Teleflex Announces Expanded Nationwide Coverage for the UroLift System for Patients with Enlarged Prostate
June 26 2019 - 6:45AM
Teleflex Incorporated (NYSE: TFX) today announced that Anthem®, one
of the nation’s leading health insurance providers is now covering
the UroLift® System, a proven, minimally invasive treatment
for men with benign prostatic hyperplasia (BPH).
Anthem insures more than 32.2 million lives nationwide through
its commercial and Medicare Advantage products. With the
announcement of this new coverage, all independent licensees of the
Blue Cross Blue Shield Association now allow members access to the
UroLift System treatment for enlarged prostate when plan-specific
medical necessity criteria are met.
“This favorable coverage decision by Anthem is a strong
affirmation of the UroLift System as an accepted standard of care
treatment for patients suffering from the burdensome symptoms of
BPH,” said Dave Amerson, President of Teleflex Interventional
Urology business unit. “More than 100,000 men have received the
UroLift System treatment worldwide, and this coverage milestone
will provide many more with rapid and durable symptom relief,
allowing patients to return to their normal routines with minimal
downtime.”
BPH, also known as enlarged prostate, is a common condition
marked by bothersome urinary symptoms that can cause loss of
productivity, depression, interrupted sleep, and decreased quality
of life.1 More than 40% of men in their 50s have BPH and over
80% of men in their 70s have BPH. If left untreated, the condition
can worsen over time and cause permanent bladder damage.2
The UroLift System is a minimally invasive approach to treating
enlarged prostate that may allow men to get off BPH medications and
avoid major surgery, while also providing rapid symptom relief and
recovery with results in days rather than months.2,3 The Prostatic
Urethral Lift procedure is recommended for the treatment of BPH in
both the American Urological Association and European Association
of Urology clinical guidelines.
About the UroLift® SystemThe FDA-cleared
UroLift System is a proven, minimally invasive technology for
treating lower urinary tract symptoms due to benign prostatic
hyperplasia (BPH). The UroLift permanent implants, delivered during
a minimally invasive transurethral outpatient procedure, relieve
prostate obstruction and open the urethra directly without cutting,
heating, or removing prostate tissue. Clinical data from a pivotal
206-patient randomized controlled study showed that patients with
enlarged prostate receiving UroLift implants reported rapid and
durable symptomatic and urinary flow rate improvement without
compromising sexual function.*3 Patients also experienced
significant improvement in quality of life. Over 100,000 men have
been treated with the UroLift System worldwide. Most common adverse
events reported include hematuria, dysuria, micturition urgency,
pelvic pain, and urge incontinence. Most symptoms were mild to
moderate in severity and resolved within two to four weeks after
the procedure. The Prostatic Urethral Lift procedure using the
UroLift System is recommended for the treatment of BPH in both the
American Urological Association and European Association of Urology
clinical guidelines. The UroLift System is available in the U.S.,
Europe, Australia, Canada, Mexico and South Korea. Learn more
at www.UroLift.com.
About Teleflex Interventional UrologyThe
Teleflex Interventional Urology Business Unit is dedicated to
developing innovative, minimally invasive and clinically effective
devices that address unmet needs in the field of urology. Our
initial focus is on improving the standard of care for patients
with BPH using the UroLift System, a minimally invasive permanent
implant system that treats symptoms while preserving normal sexual
function.*3 Learn more at www.NeoTract.com.
About Teleflex IncorporatedTeleflex is a global
provider of medical technologies designed to improve the health and
quality of people’s lives. We apply purpose driven innovation – a
relentless pursuit of identifying unmet clinical needs – to benefit
patients and healthcare providers. Our portfolio is diverse, with
solutions in the fields of vascular and interventional access,
surgical, anesthesia, cardiac care, urology, emergency medicine and
respiratory care. Teleflex employees worldwide are united in the
understanding that what we do every day makes a difference. For
more information, please visit www.Teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®,
Pilling®, Rusch®, UroLift® and Weck® – trusted brands
united by a common sense of purpose.
Contacts:For Teleflex Incorporated:Jake Elguicze,
610.948.2836Treasurer and Vice President, Investor Relations
Media:Nicole Osmer, 650.454.0504nicole@healthandcommerce.com
1. Speakman et al. 2014 BJUI Internationa.l 2. Tubaro et
al. 2003 Drugs Aging. 3. Roehrborn, J Urology 2013 LIFT Study.*No
instances of new, sustained erectile or ejaculatory
dysfunction.
MAC01109-01 Rev A
Teleflex (NYSE:TFX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Teleflex (NYSE:TFX)
Historical Stock Chart
From Apr 2023 to Apr 2024